Open AccessIntermediate dose cytarabine in treatment myeloid sarcoma of the bilateral breast after allogeneic stem cell transplantation
Author(s) -
Mozaffar Aznab,
Mansour Khazaie
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.174174
Subject(s) - medicine , cytarabine , mitoxantrone , myeloid sarcoma , myeloid leukemia , transplantation , autologous stem cell transplantation , chemotherapy , mastectomy , oncology , surgery , myeloid , stem cell , hematopoietic stem cell transplantation , breast cancer , cancer , biology , genetics
Myeloid sarcoma can be occurred bofore acute myeloid leukemia, concomitantly, at relapse or after allogenic stem cell transplantation, rarely. In this investigation, we reported a 38-year-old woman with a history of AML relapsed 9 months after allo-SCT as an MS in the bilateral breast. She underwent bilateral mastectomy. The patient was a candidate for systemic chemotherapy. An intermediate dose of cytarabine with mitoxantrone was considered for the patient, and it was repeated at the specified intervals. Currently, the patient is still being followed up, and there is no sign of local or systemic recurrence.